REGEN Biotech

Feature Event

• About Regen BiotechREGEN Biotech is the research-oriented bio-venture company focusing on commercializing products that were co- developed with the Medical Science Center at KIST, Biology Department of KAIST, and many other leading research institutes in Korea. REGEN Biotech possesses the world’s leading technology of fabricating scaffolds for therapeutic tissue regeneration using biocompatible polymer and regenerative peptides. PowerPol® is the first innovative scaffold for dermal tissue regeneration applied to penile enlargement, and β-infra ® is an early detection kit for kidney disease, developed to detect regenerative protein that is excreted in urine upon kidney damage. Both products have been successfully launched with Korea Food & Drug Administration (KFDA) approval. 30 Dec 2020
• Natalia Markova became a medical adviser to Regen BiotechThe head of Medical Esthetic, Natalia Markova, became a medical adviser to the South Korean laboratory of Regen Biotech, Inc in the European Union.South Korean laboratory Regen Biotech is a manufacturer of fillers based on polylactic acid - Aesthefill and Powerfill. As a medical adviser, Natalya Markova will participate in the scientific developments of the company and give lectures in the countries of the European Union. Since October of this year, Medical Esthetic is a trusted representative of Powerfill in Russia, where this drug is already registered. In addition, Medical Esthetic is the distributor of Aesthefill in Europe. It is planned that at the beginning of next year this filler will receive European certification. Aesthefill and Powerfill are polylactic acid based fillers. Unlike traditional fillers, they stimulate the production of your own collagen. Aesthefill replenishes the volume on the face, effectively smoothes wrinkles and fills wrinkles. Powerfill is used to increase volume in the lower legs, buttocks and intimate area. 30 Dec 2020
• CAUH Prof. Kim Beom Joon Presents Research on Efficacy of PDLA FillerVolumetric deficiencies are increasingly recognized as a major component of the ageing process, and the use of injectable fillers has steadily increased. Soft-tissue augmentation with Hyaluronic acid (HA) fillers has been the most frequently used treatment to correct facial wrinkles. However, the efficacy of HA fillers is short-lived. A new type of filler was developed whose efficacy was recently studied by researchers at Chung-Ang University Hospital (CAUH). For the first time in Korea’s medical history, CAUH researchers confirmed the efficacy and safety of poly-DL-lactic acid (PDLA, Aesthefill®), which promotes volumization through the production of collagen. Researchers led by Prof. Kim Beom-Joon of the Department of Dermatology, studied the efficacy of injection with PDLA fillers compared with HA fillers, and found out that both injections provide comparable efficacy and safety. In this comparative study, 58 Koreans with deep nasolabial folds were randomized for injections with PDLA or HA into both nasolabial folds and observed for 24 weeks. Efficacy was determined by calculating the changes in Wrinkle Severity Rating Scale (WSRS)  relative to baseline, and local safety was assessed by reported adverse events. At week 24, mean improvement in WSRS from baseline was 2.09±0.68 for the PDLA side and 1.54 ±0.65 for the HA side. Both injections were well tolerated, and the adverse reactions were mild and transient in most cases. PDLA promotes volumization through the production of collagen and vascularization of existing collagen, whereas Hyaluronic Acid is injected to the wrinkle to replace lost volume. The major difference of PDLA filler from exiting fillers is that it facilitates the formation of collagen and thus the efficacy is amplified 3-6 months after the injection. PDLA with a porous wall structure has been developed and used overseas, as a filler to stimulate collagen production, providing better volume results. It was only recently that a Korean company (REGEN Biotech) developed PDLA filler, Aesthefill®, using its independent technology.  “Since Aesthefill® has equal-sized particles, it provides more natural results with less pain compared to exiting PLA fillers. Introduction of Aesthefill® is expected to facilitate the research and development of other types of filler materials in Korea”, Professor Kim said. CAUH researchers’ study is recently published in Clinical and Experimental Dermatology (SCI Journal) and is scheduled to be published in the March 2015 issue of the Journal of Plastic and Reconstructive Surgery. 30 Dec 2020